Welcome to our online store!

More Views

Femoston (estradiol, dydrogesterone) 2mg/10mg 28 tablets Фемостон

Product sku: MD3436

Availability: In stock

Only 24 left


Quick Overview

Drugs for the treatment of diseases of the genitourinary system and sex hormones. Progestogens in combination with estrogens. Dydrogesterone and estrogen.



FEMOSTON Indications

Hormone replacement therapy (HRT) to eliminate the symptoms caused by estrogen deficiency in menopausal women, not earlier than 12 months after the last menstrual period.

Prevention of osteoporosis in postmenopausal women at high risk of fractures. FEMOSTON® should be used in patients only in case of intolerance or contraindications to the use of other drugs for the prevention of osteoporosis (see section "Special instructions").

Experience in the treatment of women over 65 years of age is limited.


- Diagnosed in the past, existing or suspected breast cancer;

- established or suspected estrogen-sensitive tumors (eg endometrial cancer);

- established or suspected progestogen-sensitive tumors (eg meningioma);

- vaginal bleeding of unknown origin;

- untreated endometrial hyperplasia;

- venous thromboembolism, present now or in the anamnesis (deep vein thrombosis, thromboembolism

pulmonary arteries);

- the presence of thrombophilic disorders (eg deficiency of protein C, protein S or

antithrombin, see section "Features of application");

- acute or recent thromboembolic arterial disease (eg angina, myocardial infarction);

- acute liver disease or a history of liver disease, if liver function tests are not normalized;

- porphyria;

- known hypersensitivity to the active substances or to any of the excipients


Dosage & Administration

FEMOSTON® should be administered orally daily in a continuous combination regimen as described below.

Take 1 tablet daily during each 28-day cycle. Each blister is intended for treatment for 28 days. Then start a new cycle immediately. Such successive cycles of treatment are continuous.

For the treatment of estrogen deficiency in postmenopausal women, the lowest effective dose should be taken as the initial and maintenance dose, and the duration of the treatment period should be as short as possible (see also section "Special warnings and precautions for use").

Continuous combination therapy can be started with FEMOSTON®CONTI depending on the time elapsed since the onset of menopause and the severity of symptoms. Women who have menopausal naturally can start treatment 12 months after their last period. Women who have undergone menopause as a result of surgery can start treatment immediately.

The dose should be selected individually depending on the clinical response.

In women who are not receiving hormone replacement therapy, or in women who are switching from continuous combination hormone replacement therapy, treatment can be started at any convenient day. In women switching from cyclic or continuous sequential hormone replacement therapy, treatment should be started immediately the day after the previous cycle.

If a dose is missed, it should be taken as soon as possible. If more than 12 hours have passed, it is recommended to continue treatment with the next pill without taking the missed pill. In such cases, a missed pill may increase the likelihood of breakthrough bleeding or bleeding.

FEMOSTON® can be taken with or without food.


The drug is not intended for use in children.


Product Tags

Use spaces to separate tags. Use single quotes (') for phrases.